New Insight Wealth Advisors Has $355,000 Stock Position in Moderna, Inc. (NASDAQ:MRNA)

New Insight Wealth Advisors raised its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 4.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,545 shares of the company’s stock after buying an additional 358 shares during the quarter. New Insight Wealth Advisors’ holdings in Moderna were worth $355,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Intrinsic Value Partners LLC raised its holdings in shares of Moderna by 91.1% during the third quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company’s stock valued at $3,435,000 after acquiring an additional 24,505 shares during the period. Banco Santander S.A. acquired a new stake in Moderna during the 3rd quarter valued at $3,550,000. John G Ullman & Associates Inc. lifted its holdings in shares of Moderna by 341.3% in the third quarter. John G Ullman & Associates Inc. now owns 49,650 shares of the company’s stock valued at $3,318,000 after purchasing an additional 38,400 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Moderna by 11.6% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock worth $107,885,000 after buying an additional 167,596 shares during the period. Finally, abrdn plc grew its holdings in shares of Moderna by 28.1% during the fourth quarter. abrdn plc now owns 315,912 shares of the company’s stock valued at $12,842,000 after buying an additional 69,360 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

MRNA has been the topic of several research reports. Bank of America dropped their price objective on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a research note on Tuesday, February 11th. Hsbc Global Res raised shares of Moderna from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th. The Goldman Sachs Group cut Moderna from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $99.00 to $51.00 in a research report on Wednesday, January 29th. JPMorgan Chase & Co. set a $45.00 target price on Moderna in a research report on Friday, February 14th. Finally, Piper Sandler restated an “overweight” rating and set a $69.00 price target (down previously from $115.00) on shares of Moderna in a research note on Monday, November 18th. Four equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $60.63.

Moderna Trading Up 3.8 %

Shares of MRNA stock opened at $35.61 on Monday. The company has a market capitalization of $13.74 billion, a P/E ratio of -3.84 and a beta of 1.86. Moderna, Inc. has a 12 month low of $29.25 and a 12 month high of $170.47. The stock has a 50 day moving average of $36.60 and a two-hundred day moving average of $48.77.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.